NCT00104897View on ClinicalTrials.gov

17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Malignant Melanoma

PHASE2CompletedINTERVENTIONAL

Enrollment

25

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions

Melanoma (Skin)

Interventions

DRUG

tanespimycin

Trial Locations (2)

CB2 2QQ

Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust, Cambridge

SM2 5PT

Royal Marsden NHS Foundation Trust - Surrey, Sutton

Sponsors

Lead Sponsor

Cancer Research UK

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Cancer Research UK

OTHER

NCT00104897 - 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Malignant Melanoma | Biotech Hunter | Biotech Hunter